Analyst firms · J.P. Morgan · CERE

J.P. Morgan CERE price target and rating history

Cerevel Therapeutics Holdings Inc. (CERE) · Health Care

J.P. Morgan rates Cerevel Therapeutics Holdings Inc. (CERE) Neutral with a $25 price target, as of its latest action on Nov 20, 2023. It has published 3 rating actions on CERE since January 2022, including 0 upgrades and 1 downgrade.

Current rating
Neutral
Price target
$25
Median target, all firms
Too few
Actions on CERE
3

J.P. Morgan price target on CERE

$50$38$252023202420252026
J.P. Morgan price target on CERE, each point a stated target, January 2022 to November 2023.

Every J.P. Morgan rating on CERE

Questions about J.P. Morgan and CERE

What is J.P. Morgan's price target for CERE?
J.P. Morgan's latest stated price target for Cerevel Therapeutics Holdings Inc. (CERE) is $25, from its action on Nov 20, 2023.
What is J.P. Morgan's rating on CERE?
J.P. Morgan rates CERE Neutral, a neutral rating, as of Nov 20, 2023.
When did J.P. Morgan last change its view on CERE?
On Nov 20, 2023, J.P. Morgan resumes coverage at Neutral, price target $25.

More CERE rating histories

All J.P. Morgan ratingsCERE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.